WARMINSTER, Pa. , Oct. 02, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Mark J. Murray , Arbutus’ President and Chief Executive Officer, will present at the Chardan Genetic...

WARMINSTER, Pa. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia , Arbutus’ Chief Scientific Officer, will participate in the Hepatitis B Functional

ONPATTRO Approval Triggers Royalty to Arbutus Clinically Validated LNP Technology Now in the Hands of Genevant to Develop RNA-based Products WARMINSTER, Pa. , Aug. 13, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic

WARMINSTER, Pa. , Aug. 09, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS ), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that Dr. Michael Sofia , Arbutus’ Chief Scientific Officer, will present a corporate update at the Wedbush

- Phase 1a/1b study of AB-506, a second-generation oral capsid inhibitor, initiated - Phase 1a/1b study of AB-452, a novel and proprietary oral RNA destabilizer, expected to begin in the second half of 2018 - All oral combination Phase 2 study of AB-506 and AB-452 expected to begin by the end of

WARMINSTER, Pa. , July 19, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it has scheduled its second quarter financial results, conference call and webcast for Thursday, August 2,

First Subject Dosed in Phase 1 Study of AB-506, Arbutus’ Second-Generation Capsid Inhibitor All-Oral Combination Study of AB-506 and AB-452 Expected in 2019 HBsAg Reduction Data from ARB-1467 Expected in Q4 Arbutus Spinout Genevant Enters Transformative Partnership with Leading mRNA Therapeutics

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 18, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced that it will present at the first annual Roivant Pipeline Day on July 10, 2018

VANCOUVER, British Columbia and WARMINSTER, Pa. , June 07, 2018 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq:ABUS), an industry-leading Hepatitis B Virus (HBV) therapeutic solutions company, today announced the appointment of David Hastings as Chief Financial Officer, effective June

Two Novel HBV Candidates Planned to Enter Clinical Development in 2018 GalNAc Conjugated RNAi Agent Nominated to Enter IND-Enabling Studies Strategic Partnership with Roivant to Launch Genevant, an RNA Therapeutics Company Company to Host a Corporate Update Conference Call Today at 4:30 PM ET